Arrowhead Provides Response to New Minority Shareholder Announcement
January 09 2017 - 4:06AM
Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded
to the announcement by Silence Therapeutics plc that it acquired,
in the open-market, an equity stake of 6,000,359 Arrowhead shares,
representing 8.4% of the common shares outstanding. Arrowhead was
advised of this just prior to the announcement by Silence.
There have been no discussions about any potential transaction
between the two companies. Arrowhead’s plans to develop its
RNAi-based drug candidates ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2,
ARO-LPA, ARO-AMG1, and other undisclosed programs, are unchanged
and unaffected by this announcement. The company will also continue
to seek partnerships and collaborations that maximize the value of
its assets, as such opportunities may arise in the future.
Arrowhead president and CEO, Chris Anzalone, remarked, “We
remain focused on advancing our programs in a way that maximizes
stockholder value. While we welcome Silence as a stockholder, its
recently announced stake in Arrowhead does not change our focus or
strategic plans in any way.”
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat
intractable diseases by silencing the genes that cause them. Using
a broad portfolio of RNA chemistries and efficient modes of
delivery, Arrowhead therapies trigger the RNA interference
mechanism to induce rapid, deep, and durable knockdown of target
genes. RNA interference, or RNAi, is a mechanism present in living
cells that inhibits the expression of a specific gene, thereby
affecting the production of a specific protein. Arrowhead’s
RNAi-based therapeutics leverage this natural pathway of gene
silencing.
For more information, please visit www.arrowheadpharma.com, or
follow us on Twitter @ArrowheadPharma. To be added to the Company's
email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including the safety and efficacy of our
product candidates, the duration and impact of regulatory delays in
our clinical programs, our ability to finance our operations, the
future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our
markets, and the enforcement of our intellectual property rights.
Our most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors
that may affect our business, results of operations and financial
condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or
circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109005489/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone,
CFA626-304-3400ir@arrowheadpharma.comInvestor Relations:The
Trout GroupChad
Rubin646-378-2947ir@arrowheadpharma.comMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024